Summary
Global Markets Direct’s, ‘Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2016’, provides an overview of the Hematopoietic Stem Cell Transplantation pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Hematopoietic Stem Cell Transplantation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hematopoietic Stem Cell Transplantation and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hematopoietic Stem Cell Transplantation
- The report reviews pipeline therapeutics for Hematopoietic Stem Cell Transplantation by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hematopoietic Stem Cell Transplantation therapeutics and enlists all their major and minor projects
- The report assesses Hematopoietic Stem Cell Transplantation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hematopoietic Stem Cell Transplantation
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hematopoietic Stem Cell Transplantation
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hematopoietic Stem Cell Transplantation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Actinium Pharmaceuticals, Inc.
Athersys, Inc.
BioLineRx, Ltd.
Cell2B S.A.
Celldex Therapeutics, Inc.
FibroGen, Inc.
Novartis AG
P2D Bioscience
Polyphor Ltd.
TaiGen Biotechnology Co., Ltd.
Targazyme, Inc.
TikoMed AB
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hematopoietic Stem Cell Transplantation Overview 7
Therapeutics Development 8
Pipeline Products for Hematopoietic Stem Cell Transplantation - Overview 8
Hematopoietic Stem Cell Transplantation - Therapeutics under Development by Companies 9
Hematopoietic Stem Cell Transplantation - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Hematopoietic Stem Cell Transplantation - Products under Development by Companies 12
Hematopoietic Stem Cell Transplantation - Companies Involved in Therapeutics Development 13
Actinium Pharmaceuticals, Inc. 13
Athersys, Inc. 14
BioLineRx, Ltd. 15
Cell2B S.A. 16
Celldex Therapeutics, Inc. 17
FibroGen, Inc. 18
Novartis AG 19
P2D Bioscience 20
Polyphor Ltd. 21
TaiGen Biotechnology Co., Ltd. 22
Targazyme, Inc. 23
TikoMed AB 24
Hematopoietic Stem Cell Transplantation - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
Actimab-B - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
balixafortide - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
BL-8040 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
burixafor - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Casin - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
CDX-301 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
CordSafe - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
FG-6874 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
HSC-835 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
IBsolvMIR - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Iomab-B - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
PF-05285401 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
POL-5551 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
TZ-101 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Hematopoietic Stem Cell Transplantation - Recent Pipeline Updates 60
Hematopoietic Stem Cell Transplantation - Dormant Projects 83
Hematopoietic Stem Cell Transplantation - Discontinued Products 84
Hematopoietic Stem Cell Transplantation - Product Development Milestones 85
Featured News & Press Releases 85
Apr 06, 2016: Actinium Announces Webinar to Discuss SIERRA Trial -- Upcoming Pivotal, Phase 3 Clinical Study for Iomab-B 85
Mar 30, 2016: Actinium Receives Orphan Drug Designation From FDA for Iomab-B in Treating Refractory and Relapsed Acute Myeloid Leukemia in Elderly Patients 86
Mar 23, 2016: BioLineRx Announces Initiation of Phase 2 Trial for BL-8040 as Novel Stem Cell Mobilization Treatment 87
Mar 08, 2016: Actinium Pharmaceuticals Announces Filing of Provisional Patent Application Related to Commercial Scale Labeling and Processes for Iomab-B 87
Feb 20, 2016: Celldex Presents Preliminary Cohort Data from Pilot Study of CDX-301 in Allogeneic Hematopoietic Stem Cell Harvest at the 2016 BMT Tandem Meeting 88
Feb 02, 2016: Actinium Pharmaceuticals Announces Participation at Upcoming Annual Meeting of Pre-Eminent Blood and Marrow Transplant Organization 89
Nov 30, 2015: Actinium to Present on Iomab-B at 8th Annual LD Micro Main Event Conference on December 2, 2015 90
Apr 23, 2015: Targazyme Announces FDA Concurrence On Targazyme’s Special Protocol Assessment For A Planned Phase 3 Registration Trial For The Treatment Of Patients With Hematologic Malignancie 90
Mar 18, 2015: TaiGen Biotechnology Announces Burixafor Collaboration with Cellex and the University Hospital Carl Gustav Carus Dresden in Germany 91
Mar 17, 2015: Targazyme and M.D. Anderson Cancer Center Receive FDA IND Clearance for Phase I/II Study of TZ101-Treated Regulatory T Cells to Prevent Graft vs Host Disease in Patients Eligible for Hematologic Stem Cell Transplantation 91
Appendix 93
Methodology 93
Coverage 93
Secondary Research 93
Primary Research 93
Expert Panel Validation 93
Contact Us 93
Disclaimer 94
List of Tables
Number of Products under Development for Hematopoietic Stem Cell Transplantation, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Hematopoietic Stem Cell Transplantation - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016 13
Hematopoietic Stem Cell Transplantation - Pipeline by Athersys, Inc., H1 2016 14
Hematopoietic Stem Cell Transplantation - Pipeline by BioLineRx, Ltd., H1 2016 15
Hematopoietic Stem Cell Transplantation - Pipeline by Cell2B S.A. , H1 2016 16
Hematopoietic Stem Cell Transplantation - Pipeline by Celldex Therapeutics, Inc., H1 2016 17
Hematopoietic Stem Cell Transplantation - Pipeline by FibroGen, Inc., H1 2016 18
Hematopoietic Stem Cell Transplantation - Pipeline by Novartis AG, H1 2016 19
Hematopoietic Stem Cell Transplantation - Pipeline by P2D Bioscience, H1 2016 20
Hematopoietic Stem Cell Transplantation - Pipeline by Polyphor Ltd., H1 2016 21
Hematopoietic Stem Cell Transplantation - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2016 22
Hematopoietic Stem Cell Transplantation - Pipeline by Targazyme, Inc., H1 2016 23
Hematopoietic Stem Cell Transplantation - Pipeline by TikoMed AB, H1 2016 24
Assessment by Monotherapy Products, H1 2016 25
Number of Products by Stage and Target, H1 2016 27
Number of Products by Stage and Mechanism of Action, H1 2016 29
Number of Products by Stage and Route of Administration, H1 2016 31
Number of Products by Stage and Molecule Type, H1 2016 33
Hematopoietic Stem Cell Transplantation Therapeutics - Recent Pipeline Updates, H1 2016 60
Hematopoietic Stem Cell Transplantation - Dormant Projects, H1 2016 83
Hematopoietic Stem Cell Transplantation - Discontinued Products, H1 2016 84
List of Figures
Number of Products under Development for Hematopoietic Stem Cell Transplantation, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Assessment by Monotherapy Products, H1 2016 25
Number of Products by Targets, H1 2016 26
Number of Products by Stage and Targets, H1 2016 26
Number of Products by Mechanism of Actions, H1 2016 28
Number of Products by Stage and Mechanism of Actions, H1 2016 28
Number of Products by Routes of Administration, H1 2016 30
Number of Products by Stage and Routes of Administration, H1 2016 30
Number of Products by Molecule Types, H1 2016 32
Number of Products by Stage and Molecule Types, H1 2016 32
